Persistence of Biological Treatment and Inhibitors of Jak Kinases in Patients With Rheumatoid Arthritis.

  • STATUS
    Recruiting
  • End date
    Dec 31, 2026
  • participants needed
    540
  • sponsor
    Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Updated on 24 November 2021

Summary

One-center observational study aimed at determining the survival of patients with rheumatoid arthritis treated with targeted synthetic disease-modifying drugs (FAMEsd) and biologic disease-modifying drugs (FAMEb).

These patients will be administered a series of medications and a follow-up will be carried out to analyze their evolution.

Description

One-center observational study aimed at determining the survival of patients with rheumatoid arthritis treated with targeted synthetic disease-modifying drugs (FAMEsd) and biologic disease-modifying drugs (FAMEb).

The drugs to be administered to patients are:

  • JAK-type kinase inhibitors.
  • Monoclonal antibodies against TNF.
  • Soluble receptor against TNF.
  • Biosimilar FAMEb.
  • Rituximab.
  • Abatacept.
  • Drugs that block IL6.

A follow-up will be carried out at 12, 24, 48, 60, 72 and 84 months from the start of treatment, to analyze how the patient's health improves.

Details
Condition Rheumatoid Arthritis (Pediatric), Rheumatoid Arthritis
Clinical Study IdentifierNCT05062421
SponsorFundación Pública Andaluza para la gestión de la Investigación en Sevilla
Last Modified on24 November 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Patients aged 18 years
With a diagnosis of Adult Rheumatoid Arthritis according to the 2010 ACR / EULAR criteria
Who have received at least one of the doses of the study drugs
In follow-up in the consultations of the UGC of Rheumatology of the HUVM
With at least two complete evaluations (baseline and final) of clinical variables

Exclusion Criteria

Patients where the medical records lack sufficient baseline and final variables to perform the analysis
Patients in whom more than 50% of the variables to be collected are missing in the data collection
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note